Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida EM, Wong J, Rossi C, Butt ZA, Bartlett S, Pearce ME, Samji H, Cook D, Alvarez M, Chong M, Tyndall M, Krajden M, Janjua NZ.
Darvishian M, et al.
J Viral Hepat. 2020 Mar;27(3):243-260. doi: 10.1111/jvh.13228. Epub 2019 Dec 2.
J Viral Hepat. 2020.
PMID: 31664755